Jidan Biotech: Announcement on the Evaluation Report of the 2025 “Improving Quality, Increasing Efficiency and Focusing on Returns” Action Plan
Securities code: 603387 Securities abbreviation: Jidan Biotechnology Announcement number: 2026-017
Jidan Biotechnology Co., Ltd.
Announcement on the Evaluation Report of the 2025 “Improving Quality, Increasing Efficiency and Focusing on Returns” Action Plan
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
In order to implement the spirit of the Central Economic Work Conference and the Central Financial Work Conference and implement the requirements of the Shanghai Stock Exchange's "Initiative on Carrying out the Special Action of "Improving Quality, Increasing Efficiency and Emphasis on Return" for Shanghai-listed Companies", Jidan Biotechnology Co., Ltd. (hereinafter referred to as the "Company") held the 11th meeting of the fourth board of directors on April 29, 2026. The meeting reviewed and approved the "Proposal on the Evaluation Report of the 2025 "Improving Quality, Efficiency and Emphasis on Return" Action Plan", and the 2025 Evaluate the implementation of annual action plans.
The company summarized the implementation of the 2025 action plan of "improving quality, increasing efficiency and focusing on returns" focusing on the six major directions of "strengthening external business and increasing internal efficiency, innovation-driven product upgrades, in-depth improvement of the governance system, improving the performance of directors and senior executives, focusing on investor returns, and strengthening investor communication". The specific content of the report is as follows:
1. Strengthen the business engine externally and increase operational efficiency internally
During the reporting period, the company adhered to the two-wheel drive of externally strengthening business and internally increasing efficiency, and made two-way efforts to consolidate the foundation for development.
At the business level, the company works together in all dimensions, with revenue from self-produced products (covering POCT, chemiluminescence and others) reaching 926 million yuan. The chemiluminescence business continues to lead the way. With the small luminescence MAGICL 6000 and MAGICL 6000i as the core, the company adopts differentiated market strategies and cooperates with flexible sales policies to accelerate terminal market penetration. The company achieved more than 1,100 small luminescence units installed throughout the year. As of the end of 2025, there are 105 chemiluminescence detection projects, basically covering common clinical diseases. There are a total of 109 domestic chemiluminescence reagent registration certificates, and new registration certificates continue to consolidate market advantages in segmented fields. Thanks to the expansion of regular projects driven by small luminescent products, the annual chemiluminescence production line revenue reached 320 million yuan, a year-on-year increase of 20.58%, accounting for 34.53% of self-produced product revenue, becoming the company's core growth engine.
At the management level, the company focuses on improving internal operational efficiency and systematically promotes it from four dimensions: information construction, RPA (robotic process automation) promotion and application, data reporting automation, and AI agent pilot application. In terms of informatization construction, the company continues to build a solid digital foundation and has completed the upgrade and iteration of six core business systems including EHR (electronic human resources management), OA (office automation), ERP (enterprise resource planning), SRM (supplier relationship management), CRM (customer relationship management), and expense control. It has broken down data barriers between systems, promoted the migration of key processes from offline to online, and achieved efficient cross-department and cross-level collaboration. In 2026, the company will continue to promote the upgrade of MES (Manufacturing Execution System) and WMS (Warehouse Management System) systems to further improve the information strategic layout. In terms of RPA promotion and application, more than 100 RPA automation tasks have been deployed, replacing manual operations with automatic execution by the system, effectively releasing human resources and significantly reducing error rates. In terms of data report automation, automation tools are used to realize automatic capture, integration and visual presentation of data, promote the transformation of management reports from passive statistics to active analysis, and provide solid support for business decisions. In terms of AI agent pilots, the company carries out exploratory applications around scenarios such as intelligent question answering and document processing to accumulate experience for subsequent intelligent upgrades.
Through two-way efforts in business expansion and management improvement, the company has achieved cost reduction and efficiency improvement while further enhancing management resilience and laying a solid foundation for stable and long-term development in a complex and ever-changing external environment.
During the reporting period, the company achieved operating income of 1.0517143 million yuan, a year-on-year decrease of 9.71%. The net profit attributable to shareholders of listed companies was 220.6614 million yuan, a year-on-year decrease of 1.33%. The net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 183.936 million yuan, a year-on-year decrease of 8.96%.
2. Innovation drives product upgrades and builds self-research advantages across the entire chain
During the reporting period, the company adhered to the innovation-driven concept, continued to promote pipeline product upgrades and independent technological breakthroughs across the entire industry chain, and built a product matrix covering multi-level application scenarios and integrated self-research and production capabilities.
In terms of assembly line products, the company focuses on promoting the technological upgrade and market expansion of the Metis 6000 and Metis 7000 fully automatic biochemical immune assembly lines. Metis 6000 adopts a modular design, with a single module covering an area of about 1 square meter. It supports flexible cascading of 1 to 4 biochemical or immune modules. The immune module has a detection speed of 400 tests/hour, and the first result is as fast as 12 minutes. The biochemical module has a constant speed of 1000 tests/hour. It can optionally be equipped with a centrifugal decapping module and an independent emergency channel. Metis 7000 is positioned as the company's strategic assembly line product, integrating sample processing, refrigerated storage, automatic quality control and other functions. The immune module can measure 600 tests/hour, and the biochemical module can measure 1,600 tests/hour. The core instruments and supporting reagents are all independently developed and produced. During the reporting period, more than 80 Metis 6000 units were installed.
In the field of molecular diagnostics, the company leads innovation in molecular rapid testing with microfluidic technology. GN 7000 and GN 7120 fully automatic nucleic acid amplification analyzers realize on-site rapid testing of "sample in, result out", with results issued in as fast as 30 minutes. They are fully enclosed, pollution-free, highly sensitive, and can be stored and transported at room temperature. The supporting reagents adopt frozen pre-embedding technology and self-gravity microfluidic technology. Since its launch in December 2024, more than 320 units have been installed. By strengthening the training system and after-sales service system, the promotion and application of product terminals have been accelerated.
In terms of full-chain self-research, the company relies on the four sub-platforms of biological raw material design and synthesis, high-end experimental animals, precision component design and processing, and diagnostic research to build a complete closed-loop system from technology research and development to large-scale production. It has completed the self-production of key raw materials such as magnetic beads, microspheres, and small molecule antigens, with a self-sufficiency rate of key raw materials exceeding 90%. As of the end of 2025, the company has a total of 398 valid patents, including 65 invention patents, 300 utility model patents, and 33 appearance patents. It has added more than 1,000 new domestic and foreign product registration certificates, and product entry licenses cover 67 countries. The company will continue to increase investment in research and development, improve product performance, reduce production costs, ensure the security of the supply of core raw materials, and provide strong support for the continued growth of operating performance.
In 2025, the company will continue to implement the R&D-driven concept, with R&D investment reaching 167 million yuan, accounting for 15.89% of operating income, focusing on chemiluminescence instruments, biochemical instruments and assembly line systems.
3. Improve the level of standardized operations and improve the corporate governance system
The company has established and improved the internal control system in accordance with the law, continuously improved the corporate governance mechanism and compliance management system, optimized management processes, ensured the company's stable and compliant operations, effectively improved the efficiency of corporate governance operations and system execution, and provided a solid guarantee for the company's standardized operations and high-quality development.
In 2025, the company strictly followed the relevant procedures to implement the operations and convening of shareholders' meetings, the board of directors and special committees of the board of directors. A total of 4 board meetings, 2 shareholders' meetings, 6 special meetings of the board of directors' special committees and independent directors were held throughout the year, and all proposals were reviewed and approved.
In 2025, the company will strictly follow the requirements of the latest laws, regulations and normative documents such as the Company Law, the Securities Law, the Code of Governance of Listed Companies and the Guidelines for the Articles of Association of Listed Companies, and revise the Articles of Association, the Rules of Procedure for Shareholders' Meetings, the Rules of Procedure for the Board of Directors and other corporate governance-related systems; at the same time, it will complete the reform of the Board of Supervisors based on the actual situation of the company, cancel the Board of Supervisors and let the Audit Committee of the Board of Directors exercise the powers of the original Board of Supervisors, achieving a smooth transition of supervisory functions.
4. Strengthen the responsibilities of “key minorities” and improve the performance of directors and senior executives
The company continues to strengthen the awareness of responsible performance and risk prevention and control capabilities of the "key minority", further promotes the diligent performance of duties and responsibilities of directors and senior executives, and lays a solid foundation for the company's steady development. In 2025, the company improved relevant systems such as the "Articles of Association" and "Management System for Company Shares Held by Directors and Senior Managers and Their Changes", strictly regulated the shareholding behavior of controlling shareholders, actual controllers, directors and senior managers, and effectively improved the level of compliance operations and risk prevention awareness.
The company attaches great importance to the sustainable development of human resources, always adheres to the development concept of "talent is the first resource", and continuously improves the multi-level, full-cycle employee training system. The company pushes regulatory information to directors and senior managers from time to time, timely conveys the latest regulatory developments and typical cases, and actively organizes directors and senior executives to participate in various trainings organized by the Shanghai Stock Exchange and the Association of Listed Companies, etc., to promote directors and senior executives to perform their duties diligently and responsibly, ensure that they fully understand relevant laws, regulations and business rules, and continue to improve their compliance knowledge reserves and performance capabilities.
5. Continue to distribute cash dividends and focus on investor returns
The company attaches great importance to the protection of investors' rights and interests, actively fulfills its responsibility to return shareholders, and is committed to realizing value sharing. The company strictly abides by relevant laws, regulations and other requirements to implement shareholder dividend return planning and profit distribution policies, and gives back to shareholders with practical actions.
The cash dividend for 2024 will be completed on June 17, 2025. A cash dividend of 0.9 yuan (tax included) will be distributed for every 10 shares, with a total cash dividend of 45,643,816.53 yuan; 2 The 2025 semi-annual cash dividend was completed on September 15, 2025. A cash dividend of 0.9 yuan (tax included) was distributed for every 10 shares, with a total cash dividend of 45,643,816.53 yuan distributed. Since its listing in 2017, the company's cumulative cash dividends and repurchase cancellation amounts have reached 897 million yuan, which has exceeded the funds raised from the IPO.
6. Strengthen investor communication and understand investor demands
The company actively practices the concept of "investor-oriented" and attaches great importance to communication with investors. The company strictly abides by the "Shanghai Stock Exchange Stock Listing Rules" and other relevant information disclosure regulations, fulfills its information disclosure obligations in accordance with the law, and truthfully, accurately, completely, timely and effectively discloses periodic reports, temporary announcements and other major information to ensure that investors fully understand the company's situation. After the disclosure of the regular reports, the company successively held the 2024 and 2025 first quarter performance briefing, the 2025 half-year performance briefing and the 2025 third quarter performance briefing on the "SSE Roadshow Center" platform to interpret the contents of the regular reports, and visually displayed the annual report in the form of graphic briefings through the "Jidan Bio" public account.
The company continues to promote investor relations management in diversified ways, build multi-dimensional and multi-level investor communication channels, actively respond to investor demands, and proactively convey the company's investment value. In daily work, the company communicates with investors on a regular basis through investor relations mailboxes, investor hotlines and other channels, strengthens investor relations management, and helps all investors to keep abreast of the company's operating dynamics through various forms to promote the establishment of a good relationship between the company and investors.
7. Other matters
In 2025, the company will deeply integrate the action plan of "improving quality, increasing efficiency and focusing on returns" with the various work arrangements of the board of directors, and has achieved certain results in deepening business layout, promoting product innovation, standardizing corporate governance, and enriching investor communication methods; at the same time, it actively conveys the company's value, continues to maintain the company's good image in the capital market, and jointly promotes the stable and healthy development of the capital market.
Forward-looking statements such as company plans and development strategies involved in the progress of this "Improving Quality, Efficiency and Focusing on Returns" action plan do not constitute the company's substantive commitment to investors. Investors are kindly requested to invest rationally and pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Jidan Biotechnology Co., Ltd.
April 29, 2026